Covered — barely, and the price sits far below NAV. The $0.26 quarterly regular dividend — no supplemental was declared alongside it — was covered in the first half of 2026, but only just: net investment income was $0.25 per share in Q1 against the $0.26 dividend, then $0.28 in Q2, for $0.53 against $0.52 declared across the half. NAV slipped from $11.09 at December 31, 2025 to $11.02 at March 31, 2026 and $10.94 at June 30, 2026, and the shares closed at $8.31 on October 23, 2026 — about 24% below that June NAV. The income covers the dividend; the market is pricing the credit risk, not the coupon, at a discount.
Key risk: Middle-market credit — non-accruals were 0.6% of the portfolio at fair value at June 30, 2026 (0.2% excluding credit-support-covered positions), and a $350 million unsecured note matured in November 2026; a wave of borrower defaults or a costly refinancing would hit both NAV and the income that funds the dividend.
Changes if: Net investment income falls below the $0.26 quarterly rate for two consecutive quarters, NAV keeps falling, or the spillover cushion (about $0.84 per share at June 30, 2026) is drawn down to cover repeated shortfalls. Any of those would point to a dividend set above what the portfolio earns.
- ✓NII coverage check: First-half 2026 net investment income was $0.53 per share ($0.25 in Q1, $0.28 in Q2) against $0.52 declared — a ~98% payout on the regular dividend. Q1 alone under-earned by $0.01; Q2 over-earned by $0.02.
- !Yield check: 12.5% on the regular dividend only — $1.04 a year ÷ the $8.31 close on October 23, 2026. The income earns that rate, so the dividend is not paid out of principal on an income basis — but a 12.5% yield at a steep discount to NAV is pay for credit risk, not a safe rate.
- !NAV trend check: NAV per share fell from $11.09 at December 31, 2025 to $10.94 at June 30, 2026 — down about 1.4% in six months on unrealized depreciation, partly offset by realized gains and the terminated legacy Sierra credit support agreement, which freed about $67 million for redeployment.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.